Clinical trial-identified inflammatory biomarkers in breast and pancreatic cancers

Frontiers in Endocrinology

Endocrinology

Angela D. Clontz¹  Jing Peng²  Delisha A. Stewart³  Supradeep Madduri⁴ 

[1] Department of Nutrition, Meredith College, Raleigh, NC, United States;Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States;Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States;Nutrition Research Institute, University of North Carolina at Chapel Hill, Kannapolis, NC, United States;Nutrition Research Institute, University of North Carolina at Chapel Hill, Kannapolis, NC, United States;

关键词: inflammatory molecules;    breast cancer;    pancreatic cancer;    diagnostic biomarkers;    treatment biomarkers;    prognostic biomarkers;   

DOI  :  10.3389/fendo.2023.1106520

 received in 2022-11-23, accepted in 2023-04-04,  发布年份 2023

来源: Frontiers

【 摘 要 】

Breast cancer and pancreatic cancer are two common cancer types characterized by high prevalence and high mortality rates, respectively. However, breast cancer has been more well-studied than pancreatic cancer. This narrative review curated inflammation-associated biomarkers from clinical studies that were systematically selected for both breast and pancreatic cancers and discusses some of the common and unique elements between the two endocrine-regulated malignant diseases. Finding common ground between the two cancer types and specifically analyzing breast cancer study results, we hoped to explore potential feasible methods and biomarkers that may be useful also in diagnosing and treating pancreatic cancer. A PubMed MEDLINE search was used to identify articles that were published between 2015-2022 of different kinds of clinical trials that measured immune-modulatory biomarkers and biomarker changes of inflammation defined in diagnosis and treatment of breast cancer and pancreatic cancer patients. A total of 105 papers (pancreatic cancer 23, breast cancer 82) were input into Covidence for the title and abstract screening. The final number of articles included in this review was 73 (pancreatic cancer 19, breast cancer 54). The results showed some of the frequently cited inflammatory biomarkers for breast and pancreatic cancers included IL-6, IL-8, CCL2, CD8+ T cells and VEGF. Regarding unique markers, CA15-3 and TNF-alpha were two of several breast cancer-specific, and CA19 and IL-18 were pancreatic cancer-specific. Moreover, we discussed leptin and MMPs as emerging biomarker targets with potential use for managing pancreatic cancer based on breast cancer studies in the future, based on inflammatory mechanisms. Overall, the similarity in how both types of cancers respond to or result in further disruptive inflammatory signaling, and that point to a list of markers that have been shown useful in diagnosis and/or treatment method response or efficacy in managing breast cancer could potentially provide insights into developing the same or more useful diagnostic and treatment measurement inflammatory biomarkers for pancreatic cancer. More research is needed to investigate the relationship and associated inflammatory markers between the similar immune-associated biological mechanisms that contribute to breast and pancreatic cancer etiology, drive disease progression or that impact treatment response and reflect survival outcomes.

【 授权许可】

Unknown   
Copyright © 2023 Peng, Madduri, Clontz and Stewart